Home » IPSEN AND TERCICA TO ENTER INTO WORLDWIDE STRATEGIC COLLABORATION IN ENDOCRINOLOGY
IPSEN AND TERCICA TO ENTER INTO WORLDWIDE STRATEGIC COLLABORATION IN ENDOCRINOLOGY
Ipsen and Tercica announced that they have agreed to a worldwide strategic collaboration in endocrinology. In cross licensing agreements, Ipsen will grant to Tercica exclusive rights to sell Somatuline Autogel, a leading product in the European acromegaly market, in the United States and Canada. Tercica will grant to Ipsen exclusive rights to sell Increlex, a leading product in the United States for the treatment of short stature associated with severe Primary IGF-1 deficiency (Primary IGFD), in all regions of the world except the United States, Japan, Canada, the Middle East and Taiwan. Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=3397461)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
07May
-
14May
-
30May